Digestive Diseases and Sciences

, Volume 55, Issue 3, pp 826–835

Surveillance for Hepatocellular Carcinoma Improves Survival in Asian-American Patients with Hepatitis B: Results from a Community-Based Clinic

  • Myron J. Tong
  • Hai-En Sun
  • Carlos Hsien
  • David S. K. Lu
Original Article



Hepatocellular carcinoma (HCC) is a common malignancy in Asians with hepatitis B virus infection. HCC patients often present with poor liver function and large tumors resulting in rapid mortality. The impact of HCC surveillance and subsequent therapy on patient survival remain controversial.


We sought to determine if surveillance for HCC in a community-based clinic improve survival and, if so, identify factors that contribute to the benefit of early tumor detection.


From 1991 to 2008, alpha-fetoprotein and abdominal ultrasound examination were used as surveillance tests for HCC. The survival of HCC patients detected by surveillance was compared to patients who presented to the clinic with HCC (no surveillance). An adjusted lead-time bias interval was added to the survival time of patients who presented with HCC.


During this period, 26 patients with surveillance developed HCC while 52 patients presented with HCC. More surveillance patients had normal levels of alkaline phosphatase, alanine aminotransferase, and aspartate aminotransferase (p < 0.05–0.0001) and had tumors that were within Milan and University of California San Francisco (UCSF) criteria (p = 0.02–0.0001). The 1-, 3-, and 5-year survival rates were higher in surveillance patients and in those who received surgical or loco-regional therapies (p = 0.007–0.0001). On multivariate analysis, baseline independent factors predicting survival were single tumors (Hazard ratio [HR] 0.25, p = 0.0005), UCSF criteria (HR 0.29, p = 0.006), Child-Turcotte-Pugh class A (HR 0.45, p = 0.03), platelet counts per log10 increase (HR 0.315, p = 0.04) and aspartate aminotransferase per log10 increase (HR 5.7, p = 0.01).


Surveillance for HCC identified patients with smaller tumor burdens and more adequate liver function who were able to receive more definitive therapies. HCC surveillance improves survival and should be included as standard of care for patients with hepatitis B.


Hepatitis B Hepatocellular carcinoma Surveillance Alpha-fetoprotein Ultrasound Asian Americans 



Hepatocellular carcinoma


Hepatitis B virus




University of California San Francisco


Child-Turcotte-Pugh scoring system


Aspartate aminotransferase


Alanine aminotransferase


Hazard ratio


  1. 1.
    Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001;2:533–543.CrossRefPubMedGoogle Scholar
  2. 2.
    El-Serag HB, Rudolph LK. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–2576.CrossRefPubMedGoogle Scholar
  3. 3.
    Han KH, Kim JK. Liver cancer in Korea. Hepatol Res. 2007;37(2):S106–S109.CrossRefPubMedGoogle Scholar
  4. 4.
    Chen JG, Parkin DM, Chen QG, et al. Screening for liver cancer: results of a randomized controlled trial in Qidong, China. J Med Screen. 2003;10:204–209.CrossRefPubMedGoogle Scholar
  5. 5.
    Ikai I, Arii S, Okazaki M, et al. Report of the 17th nationwide follow-up survey of primary liver cancer in Japan. Hepatol Res. 2007;37:676–691.CrossRefPubMedGoogle Scholar
  6. 6.
    Barazani Y, Hiatt JR, Tong MJ, et al. Chronic viral hepatitis and hepatocellular carcinoma. World J Surg. 2007;31:1243–1248.CrossRefPubMedGoogle Scholar
  7. 7.
    Tong MJ, Chavalitdhamrong D, Lu DSK, et al. Survival in Asian Americans after treatments for hepatocellular carcinoma: a seven-year experience at UCLA. J Clin Gastroenterol. 2009 (in press).Google Scholar
  8. 8.
    Di Biscelglie AM, Lyra AC, Schwartz M, et al. Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol. 2003;98(9):2060–2063.Google Scholar
  9. 9.
    Alterkruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, morality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009;27(9):1485–1491.CrossRefGoogle Scholar
  10. 10.
    McCracken M, Olsen M, Chen MS Jr, et al. Cancer incidence, mortality and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean and Japanese ethnicities. CA Cancer J Clin. 2007;57:190–205.CrossRefPubMedGoogle Scholar
  11. 11.
    Chlebowski RT, Tong M, Weissman J, et al. Hepatocellular carcinoma: diagnostic and prognostic features in North American patients. Cancer. 1984;53:2701–2706.CrossRefPubMedGoogle Scholar
  12. 12.
    Stuart KE, Anand AJ, Jenkins RL. Hepatocellular carcinoma in the United States: prognostic features, treatment outcome, and survival. Cancer. 1996;77:2217–2222.CrossRefPubMedGoogle Scholar
  13. 13.
    Geller DA, Tsung A, Wallis Marsh J, et al. Outcome of 1000 liver cancer patients evaluated at the UPMC Liver Cancer Center. J Gastrointest Surg. 2006;10:63–68.CrossRefPubMedGoogle Scholar
  14. 14.
    Hwang JP, Hassan MM. Survival and hepatitis status among Asian Americans with hepatocellular carcinoma treated without liver transplantation. BMC Cancer. 2009;9:46.CrossRefPubMedGoogle Scholar
  15. 15.
    Wong GLH, Wong VWS, Tan GM, et al. Surveillance programme for hepatocellular carcinoma improves the survival of patients with chronic viral hepatitis. Liver Int. 2008;28(1):79–87.PubMedGoogle Scholar
  16. 16.
    Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130:417–422.PubMedGoogle Scholar
  17. 17.
    Mok TSK, Yeo W, Yu S, et al. An intensive surveillance program detected a high incidence of hepatocellular carcinoma among hepatitis B virus carriers with abnormal alpha-fetoprotein levels or abdominal ultrasonography results. J Clin Oncol. 2005;23(31):8041–8047.CrossRefPubMedGoogle Scholar
  18. 18.
    Chen THH, Chen CJ, Yen MF, et al. Ultrasound screening and risk factors for death from hepatocellular carcinoma in a high risk group in Taiwan. Int J Cancer. 2002;98:257–261.CrossRefPubMedGoogle Scholar
  19. 19.
    Mima S, Sekiya C, Kanagawa H, et al. Mass screening for hepatocellular carcinoma: experience in Hokkaido, Japan. J Gastroenterol Hepatol. 1994;9:361–365.CrossRefPubMedGoogle Scholar
  20. 20.
    Toyoda H, Kumada T, Kiriyama S, et al. Impact of surveillance on survival of patients with initial hepatocellular carcinoma: a study from Japan. Clin Gastroenterol Hepatol. 2006;4:1170–1176.CrossRefPubMedGoogle Scholar
  21. 21.
    Adams PC, Arthur MJ, Boyer TD, et al. Screening in liver disease: report of an AASLD clinical workshop. Hepatology. 2004;39:1204–1212.CrossRefPubMedGoogle Scholar
  22. 22.
    Schwartz M. A biomathematical approach to clinical tumor growth. Cancer. 1961;14:1272–1294.CrossRefPubMedGoogle Scholar
  23. 23.
    El-Serag HB, Lau M, Eschbach K, et al. Epidemiology of hepatocellular carcinoma in Hispanics in the United States. Arch Intern Med. 2007;167(18):1983–1989.CrossRefPubMedGoogle Scholar
  24. 24.
    Tong MJ, Sun SC, Schaeffer BT, et al. Hepatitis-associated antigen and hepatocellular carcinoma in Taiwan. Ann Intern Med. 1971;75:687–691.PubMedGoogle Scholar
  25. 25.
    Bolondi L, Sofia S, Siringo S, et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost-effectiveness analysis. Gut. 2001;48:251–259.CrossRefPubMedGoogle Scholar
  26. 26.
    Sangiovanni A, Del Ninno E, Fasani P, et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma during surveillance. Gastroenterology. 2004;126:1005–1014.CrossRefPubMedGoogle Scholar
  27. 27.
    Trevisani F, Magini G, Santi V, et al. Impact of etiology of cirrhosis on the survival of patients diagnosed with hepatocellular carcinoma during surveillance. Am J Gastroenterol. 2007;102:1022–1031.CrossRefPubMedGoogle Scholar
  28. 28.
    Pasqual S, Irurzun J, Zapater P, et al. Usefulness of surveillance programmes for early diagnosis of hepatocellular carcinoma in clinical practice. Liver Int. 2008;28(5):682–689.Google Scholar
  29. 29.
    Hwang SJ, Tong MJ, Lai PPC, et al. Evaluation of hepatitis B and C viral markers: clinical significance in Asian and Caucasian patients with hepatocellular carcinoma in the United States of America. J Gastroenterol Hepatol. 1996;11:949–954.PubMedGoogle Scholar
  30. 30.
    Tong MJ, Blatt LM, Kao JH, et al. Precore/basal core promoter mutants and hepatitis B viral DNA levels as predictors for liver deaths and hepatocellular carcinoma. World J Gastroenterol. 2006;12(41):6620–6626.PubMedGoogle Scholar
  31. 31.
    Tong MJ, Blatt LM, Kao JH, et al. Basal core promoter T1762/A1764 and precore A1896 gene mutations in hepatitis B surface antigen-positive hepatocellular carcinoma: a comparison with chronic carriers. Liver Int. 2007;27(10):1356–1363.PubMedGoogle Scholar
  32. 32.
    Yang HI, Yeh SH, Chen PJ, et al. Association between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst. 2008;100:1134–1143.CrossRefPubMedGoogle Scholar
  33. 33.
    Yuen MF, Tanaka Y, Fong DYT, et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol. 2009;50:80–88.CrossRefPubMedGoogle Scholar
  34. 34.
    Sherman M, Peltekian KM, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology. 1995;22:432–438.PubMedGoogle Scholar
  35. 35.
    Tong MJ, Blatt LM, Kao VWC. Surveillance for hepatocellular carcinoma in patients with chronic viral hepatitis in the United States of America. J Gastroenterol Hepatol. 2001;16:553–559.CrossRefPubMedGoogle Scholar
  36. 36.
    Barbara L, Nemzi G, Gaiani S, et al. Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival. Hepatology. 1992;16:132–137.CrossRefPubMedGoogle Scholar
  37. 37.
    Kubota K, Ina H, Okada Y, et al. Growth rate of primary single hepatocellular carcinoma: determine optimal screening interval with contrast enhanced computed tomography. Digest Dis Sci. 2003;48(3):581–586.CrossRefPubMedGoogle Scholar
  38. 38.
    Okada S, Okazaki N, Nose H. Follow-up examination schedule of postoperative HCC patients based on tumor volume doubling time. Hepato-Gastroenterol. 1993;40:311–315.Google Scholar
  39. 39.
    Yoshino M. Growth kinetics of hepatocellular carcinoma. Jpn J Clin Oncol. 1983;13(1):45–52.PubMedGoogle Scholar
  40. 40.
    Sheu JC, Sung JL, Chen DS, et al. Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. Gastroenterology. 1985;89:259–266.PubMedGoogle Scholar
  41. 41.
    Farianati F, Gianni S. Surveillance for hepatocellular carcinoma in cirrhosis: is it cost effective? Eur J Cancer Prev. 2001;10:111–115.CrossRefGoogle Scholar
  42. 42.
    Duffy JP, Vardanian A, Benjamin E, et al. Liver transplantation criteria for hepatocellular carcinoma should be expanded. Ann Surg. 2007;246:502–511.CrossRefPubMedGoogle Scholar
  43. 43.
    Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42(5):1208–1236.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Myron J. Tong
    • 1
    • 2
    • 3
  • Hai-En Sun
    • 1
  • Carlos Hsien
    • 1
  • David S. K. Lu
    • 4
  1. 1.The Liver CenterHuntington Medical Research InstitutesPasadenaUSA
  2. 2.Pfleger Liver Institute at UCLALos AngelesUSA
  3. 3.Division of Digestive DiseasesDavid Geffen School of Medicine at UCLALos AngelesUSA
  4. 4.Department of RadiologyDavid Geffen School of Medicine at UCLALos AngelesUSA

Personalised recommendations